Search Results - "Maltzman, Julia D" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Folate receptor-α (FOLR1) expression and function in triple negative tumors

Folate receptor-α (FOLR1) expression and function in triple negative tumors

by Necela, Brian M, Crozier, Jennifer A, Andorfer, Cathy A, Lewis-Tuffin, Laura, Kachergus, Jennifer M, Geiger, Xochiquetzal J, Kalari, Krishna R, Serie, Daniel J, Sun, Zhifu, Moreno-Aspitia, Alvaro, Aspita, Alvaro Moreno, O'Shannessy, Daniel J, Maltzman, Julia D, McCullough, Ann E, Pockaj, Barbara A, Cunliffe, Heather E, Ballman, Karla V, Thompson, E Aubrey, Perez, Edith A
Published in PloS one (27.03.2015)

Get full text

Journal Article

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis

by Mesa, Ruben A, Kiladjian, Jean-Jacques, Catalano, John V, Devos, Timothy, Egyed, Miklos, Hellmann, Andrzei, McLornan, Donal, Shimoda, Kazuya, Winton, Elliott F, Deng, Wei, Dubowy, Ronald L, Maltzman, Julia D, Cervantes, Francisco, Gotlib, Jason
Published in Journal of clinical oncology (01.12.2017)

Get full text

Journal Article

Correction: Folate receptor-α (FOLR1) expression and function in triple negative tumors

Correction: Folate receptor-α (FOLR1) expression and function in triple negative tumors

by Necela, Brian M, Crozier, Jennifer A, Andorfer, Cathy A, Lewis-Tuffin, Laura, Kachergus, Jennifer M, Geiger, Xochiquetzal J, Kalari, Krishna R, Serie, Daniel J, Sun, Zhifu, Moreno-Aspitia, Alvaro, O'Shannessy, Daniel J, Maltzman, Julia D, McCullough, Ann E, Pockaj, Barbara A, Cunliffe, Heather E, Ballman, Karla V, Thompson, E Aubrey, Perez, Edith A
Published in PloS one (30.04.2015)

Get full text

Journal Article

Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma

Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma

by Hassan, Raffit, Kindler, Hedy L, Jahan, Thierry, Bazhenova, Lyudmila, Reck, Martin, Thomas, Anish, Pastan, Ira, Parno, Jeff, O'Shannessy, Daniel J, Fatato, Penny, Maltzman, Julia D, Wallin, Bruce A
Published in Clinical cancer research (01.12.2014)

Get full text

Journal Article

Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study

Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study

by Shah, Manish A, Starodub, Alexander, Sharma, Sunil, Berlin, Jordan, Patel, Manish, Wainberg, Zev A, Chaves, Jorge, Gordon, Michael, Windsor, Kevin, Brachmann, Carrie Baker, Huang, Xi, Vosganian, Greg, Maltzman, Julia D, Smith, Victoria, Silverman, Jeffrey A, Lenz, Heinz-Josef, Bendell, Johanna C
Published in Clinical cancer research (15.08.2018)

Get full text

Journal Article

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial

by Harrison, Claire N, Vannucchi, Alessandro M, Platzbecker, Uwe, Cervantes, Francisco, Gupta, Vikas, Lavie, David, Passamonti, Francesco, Winton, Elliott F, Dong, Hua, Kawashima, Jun, Maltzman, Julia D, Kiladjian, Jean-Jacques, Verstovsek, Srdan
Published in The Lancet. Haematology (01.02.2018)

Get more information

Journal Article

A phase 2 study of simtuzumab in patients with primary, post‐polycythaemia vera or post‐essential thrombocythaemia myelofibrosis

A phase 2 study of simtuzumab in patients with primary, post‐polycythaemia vera or post‐essential thrombocythaemia myelofibrosis

by Verstovsek, Srdan, Savona, Michael R., Mesa, Ruben A., Dong, Hua, Maltzman, Julia D., Sharma, Shringi, Silverman, Jeffrey, Oh, Stephen T., Gotlib, Jason
Published in British journal of haematology (01.03.2017)

Get full text

Journal Article

A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia

A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia

by Verstovsek, Srdan, Courby, Stephane, Griesshammer, Martin, Mesa, Ruben A, Brachmann, Carrie Baker, Kawashima, Jun, Maltzman, Julia D, Shao, Lixin, Xin, Yan, Huang, Daniel, Bajel, Ashish
Published in Leukemia research (01.09.2017)

Get full text

Journal Article

Population pharmacokinetics and exposure–response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection

Population pharmacokinetics and exposure–response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection

by Gupta, Anubha, Hussein, Ziad, Hassan, Raffit, Wustner, Jason, Maltzman, Julia D., Wallin, Bruce A.
Published in Cancer chemotherapy and pharmacology (01.04.2016)

Get full text

Journal Article

Significance of Folate Receptor Alpha and Thymidylate Synthase Protein Expression in Patients with Non–Small-Cell Lung Cancer Treated with Pemetrexed

Significance of Folate Receptor Alpha and Thymidylate Synthase Protein Expression in Patients with Non–Small-Cell Lung Cancer Treated with Pemetrexed

by Christoph, Daniel C., Asuncion, Bernadette Reyna, Hassan, Biftu, Tran, Cindy, Maltzman, Julia D., O’Shannessy, Daniel J., Wynes, Murry W., Gauler, Thomas C., Wohlschlaeger, Jeremias, Hoiczyk, Mathias, Schuler, Martin, Eberhardt, Wilfried E., Hirsch, Fred R.
Published in Journal of thoracic oncology (01.01.2013)

Get full text

Journal Article

Assessment of Folate Receptor-α and Epidermal Growth Factor Receptor Expression in Pemetrexed-Treated Non–Small-Cell Lung Cancer Patients

Assessment of Folate Receptor-α and Epidermal Growth Factor Receptor Expression in Pemetrexed-Treated Non–Small-Cell Lung Cancer Patients

by Christoph, Daniel C, Reyna-Asuncion, Bernadette, Hassan, Biftu, Tran, Cindy, Maltzman, Julia D, O'Shannessy, Daniel J, Gauler, Thomas C, Wohlschlaeger, Jeremias, Schuler, Martin, Eberhardt, Wilfried E, Hirsch, Fred R
Published in Clinical lung cancer (01.09.2014)

Get full text

Journal Article

A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GS-5745 combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma

A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GS-5745 combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma

by Bendell, Johanna C., Starodub, Alexander, Huang, Xi, Maltzman, Julia D., Wainberg, Zev A., Shah, Manish A.
Published in Journal of clinical oncology (20.05.2017)

Get full text

Journal Article

A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GS-5745 combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma

A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GS-5745 combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma

by Bendell, Johanna C., Starodub, Alexander, Huang, Xi, Maltzman, Julia D., Wainberg, Zev A., Shah, Manish A.
Published in Journal of clinical oncology (01.02.2017)

Get full text

Journal Article

Results of a phase I study of GS-5745 in combination with gemcitabine and nab-paclitaxel in patients (pts) with advanced pancreatic cancer

Results of a phase I study of GS-5745 in combination with gemcitabine and nab-paclitaxel in patients (pts) with advanced pancreatic cancer

by Bendell, Johanna C., Huang, Xi, Smith, Victoria, Maltzman, Julia D., Starodub, Alexander
Published in Journal of clinical oncology (20.05.2016)

Get full text

Journal Article

A phase II, open-label, randomized study to evaluate the efficacy and safety of GS-5745 combined with nivolumab versus nivolumab alone in subjects with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma

A phase II, open-label, randomized study to evaluate the efficacy and safety of GS-5745 combined with nivolumab versus nivolumab alone in subjects with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma

by Shah, Manish A., Metges, Jean-Philippe, Chun, Patrick Youngwhan, Smith, Victoria, Maltzman, Julia D., Wainberg, Zev A.
Published in Journal of clinical oncology (20.05.2017)

Get full text

Journal Article

Evaluating collagen neoepitopes as pharmacodynamic biomarkers of GS-5745, an MMP9 inhibitor, in advanced gastric cancer

Evaluating collagen neoepitopes as pharmacodynamic biomarkers of GS-5745, an MMP9 inhibitor, in advanced gastric cancer

by Brachmann, Carrie Baker, Zhang, Yafeng, Zavodovskaya, Marianna, Hu, Jing, Maltzman, Julia D., Smith, Victoria, Xiao, Yuanyuan, Patterson, Scott D
Published in Journal of clinical oncology (01.02.2017)

Get full text

Journal Article

Results of a phase I study of GS-5745 in combination with mFOLFOX in patients with advanced unresectable gastric / GE junction tumors

Results of a phase I study of GS-5745 in combination with mFOLFOX in patients with advanced unresectable gastric / GE junction tumors

by Shah, Manish A., Starodub, Alexander, Wainberg, Zev A., Wu, Meihua, Smith, Victoria, Maltzman, Julia D., Bendell, Johanna C.
Published in Journal of clinical oncology (20.05.2016)

Get full text

Journal Article

A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GS-5745 combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma

A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GS-5745 combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma

by Bendell, Johanna C., Starodub, Alexander, Wainberg, Zev A., Wu, Meihua, Werner, Douglas, Maltzman, Julia D., Shah, Manish A.
Published in Journal of clinical oncology (20.05.2016)

Get full text

Journal Article

Updated results of a phase 1 study combining the matrix metalloproteinase 9 inhibitor GS-5745 and mFOLFOX6 in patients with advanced gastric/gastroesophageal junction cancer

Updated results of a phase 1 study combining the matrix metalloproteinase 9 inhibitor GS-5745 and mFOLFOX6 in patients with advanced gastric/gastroesophageal junction cancer

by Shah, Manish A., Starodub, Alexander, Berlin, Jordan, Brachmann, Carrie Baker, Huang, Xi, Smith, Victoria, Maltzman, Julia D., Wainberg, Zev A., Bendell, Johanna C.
Published in Journal of clinical oncology (01.02.2017)

Get full text

Journal Article

Updated results of a phase 1 study combining the matrix metalloproteinase 9 inhibitor GS-5745 with gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer

Updated results of a phase 1 study combining the matrix metalloproteinase 9 inhibitor GS-5745 with gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer

by Bendell, Johanna C., Patel, Manish R., Brachmann, Carrie Baker, Huang, Xi, Maltzman, Julia D., Smith, Victoria, Vosganian, Gregory Sumpao, Wainberg, Zev A., Starodub, Alexander
Published in Journal of clinical oncology (01.02.2017)

Get full text

Journal Article